# Data Extraction Form: Outcome Data

**Study ID**: [Auto-generated]
**Reviewer**: [Name]
**Extraction Date**: [Date]

## 1. Outcome Definition and Measurement

### Primary Outcomes

#### 1.1 Mortality
**Definition Used**: ____________________________________________________________

**Measurement**:
- [ ] All-cause mortality
- [ ] Infection-related mortality
- [ ] In-hospital mortality
- [ ] 30-day mortality
- [ ] Other: ____________________________

**Time Point**: ____________________________

**Arm 1 (Reference)**:
- Events: ____________________________
- Total: ____________________________
- Percentage: ____________________________ %
- Effect estimate: ____________________________ (95% CI: ____________________________)

**Arm 2**:
- Events: ____________________________
- Total: ____________________________
- Percentage: ____________________________ %
- Effect estimate: ____________________________ (95% CI: ____________________________)

**Arm 3**:
- Events: ____________________________
- Total: ____________________________
- Percentage: ____________________________ %
- Effect estimate: ____________________________ (95% CI: ____________________________)

**Arm 4**:
- Events: ____________________________
- Total: ____________________________
- Percentage: ____________________________ %
- Effect estimate: ____________________________ (95% CI: ____________________________)

**Arm 5**:
- Events: ____________________________
- Total: ____________________________
- Percentage: ____________________________ %
- Effect estimate: ____________________________ (95% CI: ____________________________)

#### 1.2 Clostridium difficile Infection (CDI)
**Definition Used**: ____________________________________________________________

**Diagnostic Method**:
- [ ] PCR
- [ ] Toxin EIA
- [ ] GDH + toxin
- [ ] Culture
- [ ] Other: ____________________________

**Measurement**:
- [ ] Incidence rate per 10,000 patient-days
- [ ] Incidence rate per 1,000 admissions
- [ ] Raw count
- [ ] Other: ____________________________

**Arm 1 (Reference)**:
- Events: ____________________________
- Patient-days/admissions: ____________________________
- Rate: ____________________________
- Effect estimate: ____________________________ (95% CI: ____________________________)

**Arm 2**:
- Events: ____________________________
- Patient-days/admissions: ____________________________
- Rate: ____________________________
- Effect estimate: ____________________________ (95% CI: ____________________________)

**Arm 3**:
- Events: ____________________________
- Patient-days/admissions: ____________________________
- Rate: ____________________________
- Effect estimate: ____________________________ (95% CI: ____________________________)

**Arm 4**:
- Events: ____________________________
- Patient-days/admissions: ____________________________
- Rate: ____________________________
- Effect estimate: ____________________________ (95% CI: ____________________________)

**Arm 5**:
- Events: ____________________________
- Patient-days/admissions: ____________________________
- Rate: ____________________________
- Effect estimate: ____________________________ (95% CI: ____________________________)

#### 1.3 Multidrug-Resistant Organisms (MDROs)

**Organisms Included**:
- [ ] MRSA
- [ ] VRE
- [ ] ESBL-producing Enterobacteriaceae
- [ ] CRE
- [ ] Pseudomonas aeruginosa (resistant)
- [ ] Acinetobacter (resistant)
- [ ] Other: ____________________________

**Definition Used**: ____________________________________________________________

**Arm 1 (Reference)**:
- Events: ____________________________
- Patient-days: ____________________________
- Rate: ____________________________
- Effect estimate: ____________________________ (95% CI: ____________________________)

**Arm 2**:
- Events: ____________________________
- Patient-days: ____________________________
- Rate: ____________________________
- Effect estimate: ____________________________ (95% CI: ____________________________)

**Arm 3**:
- Events: ____________________________
- Patient-days: ____________________________
- Rate: ____________________________
- Effect estimate: ____________________________ (95% CI: ____________________________)

**Arm 4**:
- Events: ____________________________
- Patient-days: ____________________________
- Rate: ____________________________
- Effect estimate: ____________________________ (95% CI: ____________________________)

**Arm 5**:
- Events: ____________________________
- Patient-days: ____________________________
- Rate: ____________________________
- Effect estimate: ____________________________ (95% CI: ____________________________)

#### 1.4 Antibiotic Consumption

**Measure Used**:
- [ ] Days of therapy (DOT) per 1,000 patient-days
- [ ] Defined daily doses (DDD) per 1,000 patient-days
- [ ] DOT per admission
- [ ] DDD per admission
- [ ] Other: ____________________________

**Antibiotic Classes**:
- [ ] All antibiotics
- [ ] Specific classes: ____________________________
- [ ] Restricted antibiotics only

**Arm 1 (Reference)**:
- Numerator: ____________________________
- Denominator: ____________________________
- Rate: ____________________________
- Effect estimate: ____________________________ (95% CI: ____________________________)

**Arm 2**:
- Numerator: ____________________________
- Denominator: ____________________________
- Rate: ____________________________
- Effect estimate: ____________________________ (95% CI: ____________________________)

**Arm 3**:
- Numerator: ____________________________
- Denominator: ____________________________
- Rate: ____________________________
- Effect estimate: ____________________________ (95% CI: ____________________________)

**Arm 4**:
- Numerator: ____________________________
- Denominator: ____________________________
- Rate: ____________________________
- Effect estimate: ____________________________ (95% CI: ____________________________)

**Arm 5**:
- Numerator: ____________________________
- Denominator: ____________________________
- Rate: ____________________________
- Effect estimate: ____________________________ (95% CI: ____________________________)

### Secondary Outcomes

#### 2.1 Length of Stay
**Definition**: ____________________________________________________________

**Arm 1 (Reference)**:
- Mean: ____________________________ (SD: ____________________________)
- Median: ____________________________ (IQR: ____________________________)
- Effect estimate: ____________________________ (95% CI: ____________________________)

**Arm 2**:
- Mean: ____________________________ (SD: ____________________________)
- Median: ____________________________ (IQR: ____________________________)
- Effect estimate: ____________________________ (95% CI: ____________________________)

**Arm 3**:
- Mean: ____________________________ (SD: ____________________________)
- Median: ____________________________ (IQR: ____________________________)
- Effect estimate: ____________________________ (95% CI: ____________________________)

**Arm 4**:
- Mean: ____________________________ (SD: ____________________________)
- Median: ____________________________ (IQR: ____________________________)
- Effect estimate: ____________________________ (95% CI: ____________________________)

**Arm 5**:
- Mean: ____________________________ (SD: ____________________________)
- Median: ____________________________ (IQR: ____________________________)
- Effect estimate: ____________________________ (95% CI: ____________________________)

#### 2.2 Antibiotic Costs
**Currency**: ____________________________
**Cost Perspective**: [ ] Hospital [ ] Healthcare system [ ] Societal

**Arm 1 (Reference)**:
- Total cost: ____________________________
- Cost per patient: ____________________________
- Effect estimate: ____________________________ (95% CI: ____________________________)

**Arm 2**:
- Total cost: ____________________________
- Cost per patient: ____________________________
- Effect estimate: ____________________________ (95% CI: ____________________________)

**Arm 3**:
- Total cost: ____________________________
- Cost per patient: ____________________________
- Effect estimate: ____________________________ (95% CI: ____________________________)

**Arm 4**:
- Total cost: ____________________________
- Cost per patient: ____________________________
- Effect estimate: ____________________________ (95% CI: ____________________________)

**Arm 5**:
- Total cost: ____________________________
- Cost per patient: ____________________________
- Effect estimate: ____________________________ (95% CI: ____________________________)

#### 2.3 Adverse Events
**Types of Events**:
- [ ] Treatment failure
- [ ] Superinfection
- [ ] Toxicity
- [ ] Other: ____________________________

**Arm 1 (Reference)**:
- Events: ____________________________
- Total: ____________________________
- Rate: ____________________________
- Effect estimate: ____________________________ (95% CI: ____________________________)

**Arm 2**:
- Events: ____________________________
- Total: ____________________________
- Rate: ____________________________
- Effect estimate: ____________________________ (95% CI: ____________________________)

**Arm 3**:
- Events: ____________________________
- Total: ____________________________
- Rate: ____________________________
- Effect estimate: ____________________________ (95% CI: ____________________________)

**Arm 4**:
- Events: ____________________________
- Total: ____________________________
- Rate: ____________________________
- Effect estimate: ____________________________ (95% CI: ____________________________)

**Arm 5**:
- Events: ____________________________
- Total: ____________________________
- Rate: ____________________________
- Effect estimate: ____________________________ (95% CI: ____________________________)

## 2. Statistical Analysis Details

**Effect Measure**:
- [ ] Risk ratio (RR)
- [ ] Odds ratio (OR)
- [ ] Hazard ratio (HR)
- [ ] Mean difference (MD)
- [ ] Standardized mean difference (SMD)
- [ ] Rate ratio
- [ ] Other: ____________________________

**Model Used**:
- [ ] Unadjusted
- [ ] Adjusted (variables: ____________________________)
- [ ] Multilevel/hierarchical
- [ ] Time series analysis
- [ ] Other: ____________________________

**Clustering Adjustment** (for cluster-RCTs):
- [ ] Yes (method: ____________________________)
- [ ] No
- [ ] N/A

## 3. Missing Data and Uncertainties

**Missing Outcome Data**:
- [ ] None reported
- [ ] Some missing (percentage: ____________________________)
- [ ] Handling method: ____________________________

**Loss to Follow-up**:
- [ ] None
- [ ] Acceptable (<10%)
- [ ] Concerning (>10%)
- [ ] Not reported

**ITT Analysis**:
- [ ] Yes
- [ ] No
- [ ] Unclear

## 4. Subgroup Analyses (if reported)

**Pre-specified Subgroups**:
- ICU vs ward: [ ] Yes [ ] No
- Baseline resistance: [ ] Yes [ ] No
- Patient characteristics: [ ] Yes [ ] No
- Other: ____________________________

**Results by Subgroup**: ____________________________
____________________________________________________________

## 5. Notes and Clarifications

**Outcome Assessment Quality**: ____________________________
____________________________________________________________

**Data Extraction Challenges**: ____________________________
____________________________________________________________

**Additional Outcomes**: ____________________________
____________________________________________________________

---

**Extraction Verification**:
- [ ] All reported outcomes extracted
- [ ] Effect estimates recorded accurately
- [ ] Confidence intervals included
- [ ] Second reviewer verification completed
- [ ] Outcome definitions match protocol
